The mixed results are a blow for bepranemab and for related antibodies that target a mid-region epitope on tau. But exploratory analyses of the results hint at a path forward for these candidates.

And they don’t need any exotic manufacturing methods — if you can produce proteins and antibodies at scale, you can probably make AbCs too. The $20 million round was led by Madrona Ventures ...